M
Mike Gaziano
Researcher at Brigham and Women's Hospital
Publications - 1
Citations - 2123
Mike Gaziano is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: HMG-CoA reductase & Placebo-controlled study. The author has an hindex of 1, co-authored 1 publications receiving 1922 citations.
Papers
More filters
Journal ArticleDOI
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent,Martin J Landray,Christina Reith,Jonathan Emberson,David C. Wheeler,Charles R.V. Tomson,Christoph Wanner,Vera Krane,Alan Cass,Jonathan C. Craig,Bruce Neal,Lixin Jiang,Lai Seong Hooi,Adeera Levin,Lawrence Y. Agodoa,Mike Gaziano,Bertram L. Kasiske,Robert J. Walker,Ziad A. Massy,Bo Feldt-Rasmussen,Udom Krairittichai,Vuddidhej Ophascharoensuk,Bengt Fellström,Hallvard Holdaas,Vladimir Tesar,Andrzej Wiecek,Diederick E. Grobbee,Dick de Zeeuw,Carola Grönhagen-Riska,Tanaji Dasgupta,David Lewis,William G. Herrington,Marion Mafham,William Majoni,K Wallendszus,Richard H. Grimm,Terje R. Pedersen,Jonathan A. Tobert,Jane Armitage,Alex Baxter,Christopher Bray,Yiping Chen,Zhengming Chen,Michael Hill,Carol Knott,Sarah Parish,David Simpson,Peter Sleight,Alan Young,Rory Collins +49 more
TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.